News

Progenics Pharmaceuticals and Wyeth Pharmaceuticals, a division of Wyeth, have submitted a supplemental New Drug Application (sNDA) to FDA, and an Extension Application to EU. It is for

Lexicon has initiated a phase 2 clinical trial of LX2931 in patients with rheumatoid arthritis. The company has also completed a drug-drug interaction (DDI) study of LX2931 with

GlaxoSmithKline (GSK) confirmed on 22nd July that it had contracts to supply 195 million doses of its pandemic (H1N1) 2009 adjuvanted influenza vaccine. It also had a variety

Bionovo has reported positive results from the phase 1B clinical trial of Bezielle (formerly BZL101), their lead drug candidate for advanced breast cancer. The primary objective of the

Impax Laboratories has reported net income of $3 million, or $0.05 per diluted share for the second quarter of 2009, as compared to $17.1 million for the prior

DOR has received FDA’s Orphan Drug Designation for Oral BDP (beclomethasone 17,21 dipropionate, or orBec). It is meant for the treatment of gastrointestinal (GI) symptoms associated with chronic

Napo Pharmaceuticals has completed the dose selection stage (Stage I) of the ADVENT trial of crofelemer, for the treatment of chronic diarrhea in people living with HIV/AIDS on

Samarion has entered into an agreement with Nebraska-based Adesta, for the nationwide installation of the SamarionSolution in long-term care and acute care facilities. The SamarionSolution is an improvement

AstraZeneca and Astellas have entered into an agreement for the co-promotion of AstraZeneca’s Symbicort Turbuhaler (budesonide/formoterol, a dry powder inhaler), for the treatment of bronchial asthma in Japan.